Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07106762) titled 'Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy' on Aug. 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Urothelial Cancer
Intervention:
Drug: Iza-bren
Drug: Cisplatin
Drug: Gemcitabine
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: October 22, 2025
Target Sample Size: 470
Countries of Recruitme...